Racioppi, Marco <br/><br/>
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.  [electronic resource] 

 -  BMC cancer  Dec 2018 
 - 1224 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-018-5134-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravesical<br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Infusion Pumps--trends<br/>Male<br/>Middle Aged<br/>Mitomycin--administration & dosage<br/>Mycobacterium bovis<br/>Neoplasm Invasiveness--pathology<br/>Prospective Studies<br/>Risk Factors<br/>Salvage Therapy--methods<br/>Time Factors<br/>Treatment Failure<br/>Urinary Bladder Neoplasms--diagnosis